Sequential Treatment With CD20/CD22/CD10-CART After CD19-CART Treatment Base on MRD in Relapsed/Refractory B-ALL

Status: Recruiting

Location: See location...

Intervention Type: Biological

Study Type: Interventional

Study Phase: Early Phase 1

SUMMARY

CD19-negative B-ALL relapses after CD19 CAR T-cell treatment have occurred in some patients. CD20/CD22/CD10 is still expressed in CD19 negative B-ALL cells which means these CD molecules may become new targets in treatment of CD19-negative relapse of B-ALL. Thus sequential treatment with CD20/CD22/CD10-CART after CD19-CART treatment in relapsed/refractory B-ALL will kill and eliminate CD19 negative B-ALL cells and prolong the remission time.

Eligibility

Participation Requirements

Sex: All

Minimum Age: 18

Maximum Age: 60

Healthy Volunteers: f

View:

• Relapsed/Refractory B-ALL patients

• Did not achieve complete remission after 2 times of standard plan chemotherapy

• Relapsed after first induction chemotherapy

• Did not response to chemotherapy before HSCT or relapsed after HSCT

• Cannot receive allo-HSCT or refuse to receive allo-HSCT

• Cell phenotype is CD19 and CD20/CD22/CD10/CD70 positive (single or combined)

• Estimated survival time is more than 3 months in leukemia

• Volunteered for this clinical trail and signed a consent form

Locations

Other Locations

China

Southern Medical University Zhujiang Hospital

RECRUITING

Guangdong

Contact Information

Primary

Yuhua Li, Ph.D

liyuhua2011gz@163.com

86-20-61643188

Backup

Sanfang Tu, Ph.D

doctortutu@163.com

86-20-62782322

Time Frame

Start Date: 2016-01-18

Estimated Completion Date: 2025-03-31

Participants

Target number of participants: 100

Treatments

Experimental: Sequential therapy with different CART

Sequential therapy With different CART including one kind of CD20/CD22/CD10-CART After CD19-CART therapy in CD19-negative relapse ALL patients, subjects will receive 1-5 x 10\^6/Kg transduced CAR T cells at one time.

Related Therapeutic Areas

Leukemia

Similar Clinical Trials

View All

Sequential Treatment With CD20/CD22/CD10-CART After CD19-CART Treatment Base on MRD in Relapsed/Refractory B-ALL

Similar Clinical Trials

Phase I Clinical Trial of Anti-CD19/20/22 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Lymphoid Malignancies (Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, B-Prolymphocytic Leukemia)

Phase I Clinical Trial of Anti-CD19/20/22 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Lymphoid Malignancies (Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, B-Prolymphocytic Leukemia)

Pilot Study of the Efficacy and Safety of Cluster of Differentiation Antigen 19 (CD19) /Cluster of Differentiation Antigen 22 (CD22) CART in the Treatment of Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia.

Pilot Study of the Efficacy and Safety of Cluster of Differentiation Antigen 19 (CD19) /Cluster of Differentiation Antigen 22 (CD22) CART in the Treatment of Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia.

A Phase I Clinical Trial of CART Cell Therapy for Refractory/ Relapsed Acute Lymphoblastic Leukemia With Unmet Needs in Children, Adolescents and Young Adults: Feasibility and Safety Study (REALL_CART).

A Phase I Clinical Trial of CART Cell Therapy for Refractory/ Relapsed Acute Lymphoblastic Leukemia With Unmet Needs in Children, Adolescents and Young Adults: Feasibility and Safety Study (REALL_CART).